Achieving a malaria-free world presents exciting scientific challenges as well as overwhelming health, equity, and economic benefits. WHO and countries are setting …
Objectives To explore the effectiveness of data sharing by randomized controlled trials (RCTs) in journals with a full data sharing policy and to describe potential difficulties …
WRJ Taylor, K Thriemer, L von Seidlein, P Yuentrakul… - The Lancet, 2019 - thelancet.com
Background Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …
Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate weeks to months following initial infection. Malaria recurrences caused by relapses are an …
A major gap in the Plasmodium vivax elimination toolkit is the identification of individuals carrying clinically silent and undetectable liver-stage parasites, called hypnozoites. This …
F Angrisano, LJ Robinson - Parasitology International, 2022 - Elsevier
Plasmodium vivax is the most geographically widespread human malaria parasite. Global malaria efforts have been less successful at reducing the burden of P. vivax compared to P …
JK Baird - Clinical Microbiology Reviews, 2019 - Am Soc Microbiol
The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …
J Landier, DM Parker, AM Thu, VI Carrara, KM Lwin… - Malaria Journal, 2016 - Springer
Falciparum malaria persists in hard-to-reach areas or demographic groups that are missed by conventional healthcare systems but could be reached by trained community members in …
JH Adams, I Mueller - Cold Spring …, 2017 - perspectivesinmedicine.cshlp.org
Plasmodium vivax is the second most prevalent cause of malaria worldwide and the leading cause of malaria outside of Africa. Although infections are seldom fatal clinical disease can …